CRL - Conference and earnings call announcements

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, at 10:00 a.m. ET; and Baird 2026 Global Healthcare Conference on Tuesday, September 15th, at 9:40 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after eac

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 9:55 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 9:50 a.m. ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presenta

Final 2025 global cohort onboarding, with applications now open for 2026 Charles River Laboratories International, Inc. (NYSE:CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the development of technologies and life-changing therapies for patients in need. "The CIP's success shows how effectively it attracts top talent and promotes innovation," said

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3rd, at 10:00 a.m. ET. Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help pharma

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, at 11:30 a.m. GMT (6:30 a.m. ET). Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products an

Charles River Laboratories International, Inc. (NYSE:CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process for Children's Hospital Los Angeles' Phase I Clinical Trials. Across its portfolio, Charles River is dedicated to advancing oncology research and leveraging new technologies and techniques to enhance the ability to deliver life-changing therapeutics to patients. Alliance with the Parker Institute for C

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, at 10:00 a.m. EDT; and Baird 2025 Global Healthcare Conference on Wednesday, September 10th, at 9:40 a.m. EDT. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after

Partnership aimed at improving cell separation and increasing cell viability Charles River Laboratories International, Inc. (NYSE:CRL) and Akadeum Life Sciences, a leader in advanced cell separation technologies, announced today the integration of Akadeum's GMP-grade Human T Cell Leukopak Isolation Kit into Charles River's Cell Therapy Flex Program. Charles River's Cell Therapy Flex Platform originated as an off-the-shelf solution for Cell Therapy Process Development, providing ready-to-use platforms and protocols validated for autologous CAR-T and TCR-T cell therapies to minimize risk, lower costs, and accelerate development timelines. Automated platforms with closed systems include pr

Supporting fast-track production of therapeutic targeting ultra-rare neurodevelopmental disease Charles River Laboratories International, Inc. (NYSE:CRL) and Elly's Team, a parent-led foundation striving to find a cure for Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS), a rare genetic disorder, have announced a plasmid DNA contract development and manufacturing organization (CDMO) agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Elly's Team accessed established gene therapy CDMO capabilities and advisory services to manufacture critical starting materials for a Phase I clinical trial. Thi

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 4th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available fo

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14th, at 8:40 a.m. PT (11:40 a.m. ET). Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services t

Charles River Laboratories International, Inc. (NYSE:CRL) today announced the initial cohort of its Charles River Incubator Program (CIP). Launched in December 2024, the program offers early-stage biotechnology pioneers access to extensive scientific and commercial expertise and a wide ecosystem of discovery, development, and manufacturing capabilities to expedite the development of technologies and life-changing therapies for patients in need. The first cohort includes six advanced therapy and technology developers: 64x Bio, Adjuva Bio, Purilogics by Donaldson, Gordian Bio, NanoPalm, and NVI Therapeutics. Participants will benefit from tailored mentorship, consultative regulatory and qual

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help p

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and serv

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12th, at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20th, at 2:00 p.m. GMT (9:00 a.m. ET). Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain availabl

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, at 9:15 a.m. EDT; and Baird 2024 Global Healthcare Conference on Tuesday, September 10th, at 10:15 a.m. EDT. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE:CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers. The Gates Institute mission at the University of Colorado Anschutz Medical Campus is to develo

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available fo

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior empty and full capsid ratios and high vector genome concentration (GC/mL), plus five LVV reference material products

HQ plasmid DNA production to support Phase I trials for gene therapy targeting Bardet-Biedl Syndrome Charles River Laboratories International, Inc. (NYSE:CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia's gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure. Ciliopathies are diseases caused by cilia dysfunction, which is a group of complex disorders caused by genetic mutations that result in defective or dysfunctional

GMP grade plasmid DNA to serve as a direct therapeutic targeting various indications Charles River Laboratories International, Inc. (NYSE:CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River's premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. Ship of Theseus is developing a proprietary suite of biologics based on the HOX family of transcription factors, which are responsible for driving the

Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy Charles River Laboratories International, Inc. (NYSE:CRL) and National University of Singapore's (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement. NUS Medicine will utilize Charles River's market leading contract development and manufacturing organization (CDMO) expertise in HQ and GMP- compliant plasmid DNA, which serves as a critical starting material for

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at 10:15 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to he

Off-the-shelf Rep/Cap simplifies gene therapy supply chains with immediate availability Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs. Following the previously announced launch of its lentiviral packaging and AAV Helper plasmid products, the addition of AAV Rep/Cap (RC2, 5, 6, 8, 9) supplements a comprehensive range of contract development and manufacturing organization (CDMO) products and services, reducing manufacturing effort by up to 66%. The ready-to-use plasmid products are produced and released according to batch pro

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and se

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services to help

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12th, at 10:10 a.m. EDT; and Baird 2023 Global Healthcare Conference on Wednesday, September 13th, at 9:05 a.m. EDT. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website afte

CDMO will perform HQ plasmid production in support of Phase I/II clinical trials for Infantile Neuroaxonal Dystrophy Charles River Laboratories International, Inc. (NYSE:CRL) and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-related neurodegeneration (PLAN), today announced a plasmid DNA manufacturing alliance. The collaboration will leverage Charles River's market leading contract development and manufacturing organization (CDMO) expertise in High Quality (HQ) plasmid DNA production, to manufacture its leading candidate for Phase I/II clinical trials. In IN

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Thursday, June 8th, at 11:00 a.m. ET. Management will present an overview of Charles River's strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for approximately t

Company also announces partner lab initiative to expand global coverage Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix® NGS). Accugenix NGS simultaneously sequences millions of individual DNA fragments from a sample and provides key information to pharmaceutical and personal care manufacturers regarding microbial control. When studying pure isolates and/or sequencing of mixed species environments, Accugenix NGS provides a deeper resolution of organism genes and variants at a level never before possible. The platform answers client questions, pr

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management will present an overview of Charles River's strategic focus and business developments. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks. About Charles River Charles River provides essential products and services to help pharmaceutical and biot

Off-the-shelf pHelper simplifies gene therapy supply chains with immediate availability Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade. Helper plasmids are the latest in a comprehensive collection of contract development and manufacturing organization (CDMO) products and services developed to simplify complex supply chains and safeguard vira

Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseases Charles River Laboratories International, Inc. (NYSE:CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. Supporting the first gene therapy platform targeting renal diseases, which affect approximately 840 million people, or around 10 percent of the global population, the program leverages Charles River's established plasmid platform, eXpDNA™, and decades of experience at the Company's plasmid DNA manufacturing center of excellence

HCP-ELISA builds upon Company's HCP-GAPex℠ service, increasing the efficiency and efficacy of HCP assay development Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of its first Enzyme-Linked Immunosorbent Assay (ELISA) Kit for the detection and quantitation of residual host cell proteins (HCP) in CHO-based biotherapeutics. Charles River's HCP ELISA kit achieves industry leading rates for sensitivity and specificity, reaching 0.1 ng/mL and 90 percent antibody coverage, respectively. This increase in sensitivity and specificity can be attributed to the unique chicken immunoglobulin Y (IgY) antibodies utilized. The Benefits of IgY Antibodies In contrast

Company will launch the eXpDNA Platform at Phacilitate Advanced Therapies Week Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of its eXpDNA™ plasmid platform, established from the Company's contract development and manufacturing (CDMO) and biologics testing experience. The platform significantly reduces plasmid development and production timelines while streamlining the development journey for cell and gene therapy and vaccine developers with a focus on product quality and consistency. The platform leverages Charles River's expertise in developing, manufacturing, and releasing more than 200 High Quality (HQ) and Good Manufacturing Practice- (GMP) comp

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10th, at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks. About Charles River Charles River provides essential products and

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Jefferies 2022 London Healthcare Conference in London, England on Wednesday, November 16th, at 10:20 a.m. GMT (5:20 a.m. ET); and Evercore ISI 5th Annual HealthCONx Conference virtually on Wednesday, November 30th, at 9:40 a.m. ET. Management will present an overview of Charles River's strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences in New York, including: Baird 2022 Global Healthcare Conference on Tuesday, September 13th, at 10:15 a.m. EDT; and Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th, at 10:00 a.m. EDT. Management will present an overview of Charles River's strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Jefferies Healthcare Conference on Wednesday, June 8th, at 10:00 a.m. ET, and at the William Blair 42nd Annual Growth Stock Conference on Thursday, June 9th, at 10:40 a.m. CT (11:40 a.m. ET). Management will present an overview of Charles River's strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two wee

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th, at 10:30 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks. About Charles River Charles River provides essential products and servic

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will virtually present at two upcoming investor conferences, including: Jefferies London Healthcare Conference on Thursday, November 18th, with a pre-recording of the presentation available starting at 8:00 a.m. GMT (3:00 a.m. ET); and Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1st, at 9:40 a.m. ET. Management will present an overview of Charles River's strategic focus and business developments. A webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay wil

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will virtually present at three upcoming investor conferences, including: Wells Fargo 2021 Healthcare Conference on Thursday, September 9th, at 10:00 a.m. EDT; Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13th, at 10:15 a.m. EDT; and Baird 2021 Global Healthcare Conference on Tuesday, September 144h, at 10:15 a.m. EDT. Management will present an overview of Charles River's strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will virtually present at three upcoming investor conferences, including: Jefferies Virtual Healthcare Conference on Tuesday, June 1st, at 10:00 a.m. ET; William Blair 41st Annual Growth Stock Conference on Wednesday, June 2nd, at 11:00 a.m. ET; and Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10th, at 11:20 a.m. ET Management will present an overview of Charles River's strategic focus and business developments. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Barclays Global Healthcare Conference on Wednesday, March 10th, at 10:20 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks. About Charles River Charles River provides essentia

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th, at 10:00 a.m. EST. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks. About Charles River Charle